Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia

Hypercholesterolemia Clinical Trial

Official title:

Evaluation of the Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Moderately Hypercholesterolemic Subjects: a Double-blind, Placebo-controlled, Randomized, Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04485793
• Other study ID #: NUT1-BO-2019
• Status: Completed
• Phase: N/A
• Start date: September 21, 2020
• Est. completion date: October 4, 2021

Study information

• Verified date: January 2024
• Source: University of Bologna
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The joint ESC/EAS guidelines for the management of dyslipidaemias recommend, for patients at low/moderate CV risk with raised LDL-C, a set of measures collectively defined as "lifestyle interventions", with use of drugs only if the LDL-C levels cannot be controlled with such lifestyle interventions. "Lifestyle interventions" also includes food supplements. The reason is the following: a simple "dietary advice" has been shown (Cochrane review and meta-analysis, Rees et al, 2013) to achieve a modest reduction of total-C and LDL-C. The review reports: Dietary advice reduced total serum cholesterol by 0.15 mmol/L (95% CI 0.06 to 0.23) and LDL cholesterol by 0.16 mmol/L (95% CI 0.08 to 0.24) after 3 to 24 months." An average reduction of LDL-C by 0.16 mmol/L (6.2 mg/dL) is definitely insufficient to control the level of LDL-C in those subjects. Therefore, those subjects would lose motivation to keep dieting. In this context, use of supplements would significantly amplify the result of diet. A significant proportion of ischemic cardiovascular events are believed to be supported by the coexistence of traditional cardiovascular risk factors such as diabetes, hypertension, dyslipidemia, smoking, and others. The aggregation of these factors is accompanied by a significant increase in the risk of cardiovascular events. Observational studies shown the existence of a relationship between cholesterolemia and coronary heart disease, clearly showing that subjects with even modestly increased total cholesterol values over time develop both fatal and non-fatal vascular events with a higher frequency compared to subjects with similar characteristics, but with lower basal values of cholesterol. Numerous controlled intervention studies, on the other hand, have shown that there is a close correlation between cholesterol reduction and cardiovascular risk; in fact, reductions in the plasma concentration of total and LDL-C, obtained through lifestyle modification or specific drugs, result in reductions in the incidence of major coronary events. The effectiveness of these interventions has been demonstrated both in subjects in primary prevention and in patients in secondary prevention.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: October 4, 2021
• Est. primary completion date: October 4, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Subjects agree to participate in the study and having dated and signed the informed consent form.
• Subjects who have the capability to communicate, to make themselves understood, and to comply with the study's requirements.
• Male or female aged = 18 years and = 70 years old.
• LDL-Cholesterol plasma levels >115 mg/dL and < 190 mg/dL.
• TG<400 mg/dL.
• Subjects who, according to the SCORE charts, have a low or moderate cardiovascular risk (defined as a total cardiovascular risk < 5%) and for whom, according to ESC/EAS guidelines 2012, the intervention strategy does not require a pharmacological lipid-lowering intervention.

Exclusion Criteria:

• Subjects already affected by cardiovascular diseases (secondary prevention) or with estimated 10 years cardiovascular disease risk> 5%;
• Obesity (BMI>30 kg/m2) or diabetes mellitus;
• Assumption of lipid lowering drugs or food supplements, or drugs potentially affecting the lipid metabolism;
• Antihypertensive treatment not stabilized since at least 3 months;
• Anticoagulants therapy
• Uncontrolled hypertension (systolic blood pressure> 190 mmHg or diastolic arterial pressure> 100 mmHg);
• Known current thyroid, gastrointestinal or hepatobiliary diseases;
• Any medical or surgical condition that would limit the patient adhesion to the study protocol;
• Abuse of alcohol or drugs (current or previous);
• History of malignant neoplasia in the 5 years prior to enrolment in the study;
• History or clinical evidence of inflammatory disease such as severe arthritis, systemic lupus erythematosus or chronic inflammatory diseases or current therapy with immunosuppressive agents or long-term glucocorticoids;
• History or clinical evidence of any significant concomitant disease that could compromise the safety of the subject or the possibility of completing the study;
• Known previous intolerance to the tested nutraceutical
• Women in fertile age not using consolidated contraceptive methods
• Pregnancy and Breastfeeding.

Related Conditions & MeSH terms

• Hypercholesterolemia

Intervention

Dietary Supplement:
• Dietary supplement
Dietary supplement formulated with 400 mg Bergamot d.e. obtained from different parts of the Citrus Bergamot whole fruit (Citrus bergamia Risso et Poiteau, fructus), specifically from fresh fruits collected from November to February (Brumex TM). Oral administration: 1 tablet/day at evening meal

Other:
• Placebo
Oral administration: 1 tablet/day at evening meal

Locations

Country	Name	City	State
Italy	University of Bologna	Bologna	BO

Sponsors (1)

Lead Sponsor	Collaborator
University of Bologna

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Pierdomenico M, Cicero AFG, Veronesi M, Fogacci F, Riccioni C, Benassi B. Effect of Citrus bergamia extract on lipid profile: A combined in vitro and human study. Phytother Res. 2023 Sep;37(9):4185-4195. doi: 10.1002/ptr.7897. Epub 2023 Jun 13. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	LDL-cholesterolemia absolute reduction from baseline and between groups	Absolute reduction of LDL-cholesterolemia after 12 weeks of treatment	12 weeks
Primary	LDL-cholesterolemia % reduction from baseline and between groups	% reduction of LDL-cholesterolemia after 12 weeks of treatment	12 weeks
Secondary	Absolute reduction from baseline and between groups in other lipid fractions, apolipoproteins and their ratios	Absolute reduction of serum concentrations of total cholesterol, HDL-cholesterol, apolipoprotein B, triglycerides and their ratios after 12 weeks of treatment	12 weeks
Secondary	% reduction from baseline and between groups in other lipid fractions, apolipoproteins and their ratios	% reduction of of serum concentrations of total cholesterol, HDL-cholesterol, apolipoprotein B, triglycerides and their ratios after 12 weeks of treatment	12 weeks
Secondary	% reduction from baseline and between groups in anthropometric parameters	% reduction of body mass index after 12 weeks of treatment	12 weeks
Secondary	% reduction from baseline and between groups in blood pressure levels	% reduction of systolic and diastolic blood pressure after 12 weeks of treatment	12 weeks
Secondary	Absolute reduction from baseline and between groups in blood pressure levels	Absolute reduction of systolic and diastolic blood pressure after 12 weeks of treatment	12 weeks
Secondary	Absolute reduction from baseline and between groups in anthropometric parameters	Absolute reduction of body mass index after 12 weeks of treatment	12 weeks
Secondary	% reduction from baseline and between groups in creatine phosphokinase (CPK) serum levels	% reduction of creatine phosphokinase (CPK) serum levels after 12 weeks of treatment	12 weeks
Secondary	Absolute reduction from baseline and between groups in creatine phosphokinase (CPK) serum levels	Absolute reduction of creatine phosphokinase (CPK) serum levels after 12 weeks of treatment	12 weeks
Secondary	Absolute reduction from baseline and between groups in liver parameters	Absolute reduction of GOT, GPT and gamma-GT after 12 weeks of treatment	12 weeks
Secondary	% reduction from baseline and between groups in liver parameters	% reduction of GOT, GPT and gamma-GT after 12 weeks of treatment	12 weeks